NEW YORK, Feb. 16, 2012 \/PRNewswire\/ -- Reportlinker.com announces that a new market research report is available in its catalogue: <\/p>\n
Future UK Microbiology Testing Market Outlook <\/p>\n
http:\/\/www.reportlinker.com\/p0771119\/Future-UK-Microbiology-Testing-Market-Outlook.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic<\/a> <\/p>\n Highlights <\/p>\n Comprehensive 978-page analysis of the UK microbiology testing market. Major issues pertaining to the UK microbiology laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Current scientific views on the definition, epidemiology, and etiology of major infectious diseases and microorganisms. Ten-year test volume and sales forecasts for nearly 80 microbiology tests performed in UK hospitals, blood banks, public health and commercial laboratories. Instrumentation technologies and feature comparison of leading analyzers. Sales and market shares of leading suppliers. Emerging diagnostic technologies and their potential market applications. Product development opportunities. Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Business opportunities and strategic recommendations for suppliers. <\/p>\n Contains 978 pages and 159 tables <\/p>\n IntroductionWorldwide Market and Technology OverviewA. Major Infectious Disease Tests1. AIDSa. Background0 Structure and Composition0 Classification0 Origin of AIDS0 Animal Lentivirus Systems0 Virus Receptos0 HIV Infections in Humans- Pathogenesis & Pathology: Overview ofHIV Infection Course0 CD4T Lymphocytes and Memory Cells0 Monocytes and Macrophages0 Lymphoid Organs0 Neural Cells0 Viral Coinfections- Clinical Findings0 Plasma Viral Load0 Pediatric AIDS- Neurologic Disease- Opportunistic Infections- Cancer0 Immunity- Virus Isolation- Serology- Detection of Viral NucleicAcid and Antigens0 Infectivity0 Epidemiology- Worldwide Spread of AIDS- United States- Routes of Transmission <\/p>\n b. Diagnostic Tests <\/p>\n 0 Laboratory Diagnosis <\/p>\n - Enzyme Immunoassay Interpretation <\/p>\n - Specific, Sensitivity, and Predictive <\/p>\n Value of Enzyme Immunoassays <\/p>\n 0 Competition Assays <\/p>\n 0 Western Blot Technique <\/p>\n 0 Immuno-Fluorescence Assay (IFA) <\/p>\n 0 Radioimmunoprecipitation <\/p>\n 0 HIV-1\/HIV-2 Combination Testing <\/p>\n 0 Methods of HIV-Antigen Detection <\/p>\n 0 Antigen Assays and Blood Screening <\/p>\n 0 Urine Tests <\/p>\n 0 Immunopathogenic Mechanism of HIV Infection <\/p>\n 0 DNA Probes <\/p>\n - Overview <\/p>\n - Quantitative Polymerase Chain Reaction <\/p>\n - In Situ PCR <\/p>\n - Needed Improvements <\/p>\n 0 Viral Load\/Drug Resistance Testing <\/p>\n 0 Genotype and Phenotype Testing <\/p>\n 0 Blood Banking Consideration <\/p>\n c. Vaccines and Drugs <\/p>\n - Antiviral Drugs <\/p>\n - Vaccines Against HIV <\/p>\n 0 Transmission of HIV in Blood Products <\/p>\n 0 HIV Transmission in Transplant and <\/p>\n Artificial Insemination Recipients <\/p>\n 2. Adenovirus <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n d. Adeno-Associated Viruses(AAV) <\/p>\n 3. Aeromonas <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 4. Anthrax\/Bacillus Anthracis <\/p>\n a. Background <\/p>\n b. Diagnostic Testsc. Vaccines and Drugs5. Arbovirusesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs6. Babesiosisa. Background7. Bacillary Epithelioid Angiomatosis (BEA)And Other Bartonella (Rochalimaea)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs8. Blastocystis Hominisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs9. Brucellaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs10. Campylobactera. Backgroundb. Diagnostic Tests0 Identification from Culturec. Vaccines and Drugs11. Candidaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs12. Chagas Diseasea. Background13. Chancroida. Backgroundb. Diagnostic Testsc. Vaccines and Drugs14. Chlamydiaa. Background0 Chlamydia Psittaci <\/p>\n 0 Chlamydia Pneumoniae <\/p>\n 0 Chlamydia Trachomatis <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 15. Clostridium Difficile <\/p>\n a. Background <\/p>\n 0 Pediatric Infections <\/p>\n 0 Epidemiology <\/p>\n b. Diagnostic Tests <\/p>\n 0 Counterimmunoelectrophoresis <\/p>\n 0 Fluorescent-Antibody Assays <\/p>\n 0 Poloymerase Chain Reactions <\/p>\n c. Drugs and Vaccines <\/p>\n 16. Coronaviruses <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 17. Coxsackieviruses <\/p>\n a. Background <\/p>\n 0 Herpangina <\/p>\n 0 Hand-foot-and-mouth syndrome <\/p>\n 0 Hepidemic Conjuctivitis <\/p>\n 0 Pharingitis <\/p>\n 0 Epidemic Pleurodynia <\/p>\n 0 Myodarditis,Pericarditis <\/p>\n 0 Overwhelming Infection of the Newborn <\/p>\n 0 Acute Aseptic Meningitis <\/p>\n 0 Undifferentiated Febrile Illness <\/p>\n 0 Fever with upper respiratory infection <\/p>\n 0 Encephalitis <\/p>\n 0 Asymptomatic Infection <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 18. Creutzfeldt-Jakob's Disease <\/p>\n a. Background <\/p>\n 0 Blood Transmission <\/p>\n b. Diagnostic Tests <\/p>\n 0 Major Commercial and Academic Players <\/p>\n - Bayer <\/p>\n - Disease Sciences\/Bio Tec Global- Imperial College of Medicine- Ortho-Clinical Diagnostics- Pall- ProMetic Life Sciences- Proteome Sciences\/Idexx- Q-One Biotech- Serono- U.S. Agricultural Research Servicec. Vaccines19. Cryptosporidium Parvuma. Backgroundb. Diagnostic Tests0 Histologic0 Laboratory Parasitology0 Serodiagnosisc. Vaccines and Drugs20. Cyclospora Cayetanensisa. Background0 Asymptomatic Infection0 Diarrhea in Immunocompetent Persons0 Diarrhea in Immunocompromisedersonsb. Diagnostic Testsc. Vaccines and Drugs21. Cytomegalovirusa. Background0 Chorioretinitis0 Gastrointestinal0 Central Nervous System Diseaseb. Diagnostic Testsc. Vaccines and Drugs22. Ebola Virusa. Background0 Epidemiology0 Hemorrhagic Feverb. Diagnostic Testsc. Vaccines and Drugs23. E. Colia. Background <\/p>\n 0 Role of Escherichia Coli in <\/p>\n Causing Diarrhea <\/p>\n 0 EPEC <\/p>\n 0 ETEC <\/p>\n 0 EIEC <\/p>\n 0 EHEC <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 24. EchoVirus <\/p>\n a. Background <\/p>\n 0 Acute Aseptic Miningitisis <\/p>\n 0 Encephalitis <\/p>\n 0 Exanthems <\/p>\n 0 Respiratory Disease <\/p>\n 0 Myope;ricarditis <\/p>\n 0 Neonatal Infections <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 25. Encephalitis <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 26. Enteroviruses <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n 0 Viral Isolation and Identification <\/p>\n 0 Antibody Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 27. Epstein-Barr Virus <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 28. Giardia Lamblia <\/p>\n a. Background <\/p>\n 0 Life Cycle and Morphology <\/p>\n 0 Morphology of Trophozoites <\/p>\n 0 Clinical Disease <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 29. Gonorrheaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs30. Granuloma Inguinalea. Backgroundb. Diagnostic Testsc. Vaccines and Drugs31. Hantavirusa. Background0 Identification of the Agent0 Transmission0 Other Rodent Hantaviruses0 Distribution0 Hantavirus Diseases0 Epidemiology0 Addendum in Proof-Northeastern Connection0 Previously Unknown Pathogens0 Cases Nationwideb. Diagnostic Tests0 An Immunohistochemistry Approach0 Hantavirus Rapid Diagnostic Test0 ELISA Diagnosis of Hantavirus PulmonarySyndrome0 IgG ELISA0 IgM Capture ELISAc. Vaccines and Drugs32. Helicobacter Pyloria. Background0 Pathogenesis0 Role in Peptic Ulcer Disease0 Role in Gastric Cancer0 Nonulcer Dyspepsiab. Diagnostic Testsc. Vaccines and Drugs0 Specific Therapeutic Regimens0 Who Should Be Treated?0 Participants in Controlled Clinical Trials <\/p>\n 0 Patients with Refractory Peptic Ulcer <\/p>\n 0 Patients with Refractory NUD <\/p>\n 0 Patients in High-Risk Groups for Gastric <\/p>\n Cancer <\/p>\n 33. Hepatitis <\/p>\n a. Background <\/p>\n b. Hepatitis A <\/p>\n c. Hepatitis B <\/p>\n d. Hepatitis C <\/p>\n 0 Classification <\/p>\n 0 Transmission of Infection <\/p>\n 0 Occupational Hazards <\/p>\n 0 Acute Hepatitis <\/p>\n 0 Diagnosis of Acute Infection <\/p>\n 0 Chronic Hepatitis <\/p>\n 0 HCV and Other Chronic Liver Diseases <\/p>\n 0 Alcoholic Liver Disease <\/p>\n 0 Hepatitis B Coinfection <\/p>\n 0 Cirrhosis and Hepatocellular Carcinoma <\/p>\n 0 Diagnostic Tests <\/p>\n 0 Possible Indications for HCV RNA Testing <\/p>\n 0 Conclusions and Future Direction <\/p>\n e. Hepatitis D <\/p>\n 0 Historical Perspective <\/p>\n 0 Epidemiology <\/p>\n 0 HBV-HDV \"Coinfection\" vs. \"Superinfection\" <\/p>\n 0 Methods of Detecting HDV <\/p>\n 0 Prevention <\/p>\n f. Hepatitis E <\/p>\n 0 Background <\/p>\n 0 Prevalence of the Disease <\/p>\n 0 Diagnostic Tests <\/p>\n 0 Epidemiologic Serosurveys <\/p>\n 0 Serologic Cross-Reactivity <\/p>\n g. Hepatitis G <\/p>\n 0 Vaccines and Drugs <\/p>\n 34. Herpes Simplex Virus <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 35. Human Herpes Virus-6 (HHV-6)a. Background0 HIV-6 Infectionsb. Diagnostic Testsc. Vaccines and Drugs36. Influenza Virusesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs37. Legionellaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs38. Lyme Diseasea. Background0 Clinical Description0 Clinical Case Definition0 Laboratory Criteria for Diagnosis0 Case Classificationb. Diagnostic Testsc. Vaccines and Drugs39. Lymphogranuloma Venereum (LGV)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs40. Malariaa. Backgroundb. Diagnostic Tests0 Potential Diagnositic Problems with PositivePatients from Non-endemic Areas- Patient- Laboratory- Physicianc. Vaccines and Drugs41. Measles (Rubeola)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs <\/p>\n 42. Meningitis <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 0 Development of Polysaccharide Vaccines <\/p>\n 0 Quadrivalent Vaccine Development <\/p>\n 0 Meningococcal A.C.Y. & W-135 Vaccines <\/p>\n 0 Efficacy of Group C Vaccine <\/p>\n 0 Efficacy of Group A Vaccine <\/p>\n 0 Combinations of Group A and C Vaccines <\/p>\n 0 Group B Efficacy Trials <\/p>\n 0 Future Direction <\/p>\n 43. Microsporidium <\/p>\n a. Background <\/p>\n 0 Prevalence and Geographic Distribution <\/p>\n 0 Sources of Human Infection and Transmission <\/p>\n b. Diagnostic Tests <\/p>\n 0 Light Microscopic Examination of Stool <\/p>\n Specimens By Chromotrope Staining <\/p>\n 0 Stool Concentration Methods <\/p>\n 0 Chemofluorescent Agents <\/p>\n 0 Giemsa Staining of Stool Specimens <\/p>\n 0 Cytologic Diagnosis <\/p>\n 0 Histologic Examination <\/p>\n 0 Electron Microscopy <\/p>\n 0 Examination of Bodily Fluids <\/p>\n 0 Examination of Tissue Sections <\/p>\n 0 Immunofluorescence Detection Procedures <\/p>\n 0 Serology <\/p>\n 0 Cell Culture <\/p>\n 0 Approach to Diagnosis <\/p>\n 0 Evaluation of Patients with Presumptive <\/p>\n Intestinal Microsporidiosis <\/p>\n 0 Evaluation of Patients with Presumptive <\/p>\n Ocular Microsporidiosis <\/p>\n c. Vaccines and Drugs <\/p>\n 44. Mononucleosis <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 45. Mumpsa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs0 Efficacy of Vaccination0 Future Issues46. Mycoplasmaa. Background0 Ureaplasma Urealyticum & Mycoplasma Hominisb. Diagnostic Testsc. Vaccines and Drugs47. Papillomavirusesa. Background0 HPV in Cancer0 Cervical Neoplasmb. Diagnostic Testsc. Vaccines and Drugs0 Prevention48. Parvovirus B19a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs49. Pneumoniaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs50. Polyomavirusesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs51. Pseudomonas Aeruginosaa. Background0 Virulence Factorsb. Diagnostic Testsc. Vaccines and Drugs52. Rabiesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs <\/p>\n 53. Respiratory Syncytial Virus (RSV) <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 54. RhinoViruses <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 55. RotaVirus (REOVIRUS) <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 56. Rubella(MEASLES) <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 0 Developing Countries <\/p>\n 0 Elimination and Eradication of Measles <\/p>\n 0 New Developments <\/p>\n 57. Salmonellosis <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 58. Septicemia <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 59. Shigellosis <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 60. Staphylococcus Aureus <\/p>\n a. Background <\/p>\n 0 The Genus Taphylococcus <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 0 Prevention <\/p>\n 61. Streptococci <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs0 Group A Streptococci0 Group B Streptococci62. Syphilisa. Backgroundb. Diagnostic Tests0 Biopsy0 Rabbit Infectivity Testing0 Other Diagnostic Modalitiesc. Vaccines and Drugs0 Syphilis and HIV Infection0 Syphilis As a Cofactor for HIV Transmission0 Basic Science Issues63. Toxoplasmosisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs64. Trichomonas Vaginalisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs65. Tuberculosisa. Backgroundb. Diagnostic Tests0 Microscopic Characteristics0 Cultural Characteristics0 Detection of Antibodies0 Skin Tests0 MDRTBc. Vaccines and Drugs66. Vibrioa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs67. West Nile Virusa. Background- Clinical Syndromesb. Diagnostic Testsc. Vaccines and Drugs <\/p>\n 68. Yersina <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n B. Instrumentation Review and Market Needs <\/p>\n 0 Abbott AxSYM <\/p>\n 0 Abbott IMx\/IMx Select <\/p>\n 0 Anagen AN2000\/AuraFlex <\/p>\n 0 Beckman Coulter Access <\/p>\n 0 BioChem Pharma\/SR1 <\/p>\n 0 BioMerieux\/Vitek Vidas <\/p>\n 0 Biotrol System 7000 <\/p>\n 0 Chiron ACS: Centaur <\/p>\n 0 Chiron ACS: 180 <\/p>\n 0 J&J Diagnostics\/Amersham Amerlite <\/p>\n 0 J&J Diagnostics Vitros ECi <\/p>\n 0 Olympus PK310 <\/p>\n 0 Roche Cobas Core <\/p>\n 0 Roche Elecsys 1010\/2010 <\/p>\n 0 Roche ES 22 <\/p>\n 0 Roche ES 33 <\/p>\n 0 Roche ES 300\/300AL <\/p>\n 0 Siemens ELISA Processor II\/III <\/p>\n 0 Siemens Immuno 1 <\/p>\n 0 Siemens\/Opus\/Plus\/Magnum <\/p>\n 0 Siemens Stratus <\/p>\n 0 Tosoh AIA-1200\/1200DX\/NexIA\/600 <\/p>\n 0 Wallac\/Pharmacia Delfia <\/p>\n C. Emerging Diagnostic Technologies <\/p>\n 1. DNA Probes <\/p>\n a. Technology Overview <\/p>\n b. Amplification Methods <\/p>\n 0 Polymerase Chain Reaction <\/p>\n - Robotics <\/p>\n - Temperature Cyclers <\/p>\n - PCR Variations <\/p>\n 0 Immuno-PCR <\/p>\n 0 QC-PCR <\/p>\n 0 DAP-PCR <\/p>\n 0 Ligase Chain Reaction0 Branched DNA0 Q-Beta Replicase0 Nucleic-Acid Sequence-Based0 Strand Displacement Activation0 Self-Sustained Sequence Replicase2. Monoclonal Antibodies3. Immunoassaysa. Technological Principleb. Enzyme Immunoassays (EIA)0 Overview0 ELISA0 Dot Immunobinding Assays0 Capillary Immunoassays0 Particle-Membrane CaptureImmunoassays0 Enzyme Amplificationc. Fluorescent Immunoassays0 Fluorescence Polarization0 Time-Resolved Pulse Fluorescenced. Luminescence0 Chemiluminescence0 Bioluminescencee. Latex Agglutinationf. Immunoprecipitation4. Differential Light Scattering5. Microcomputers and Automation6. Artificial Intelligence7. Liposomes8. Flow Cytometry9. Chromatography10. MRI11. Gel Microdroplets12. OtherD. Personal TestingE. Worldwide Business EnvironmentF. Worldwide Market StructureG. Worldwide Market Size and Growth <\/p>\n U.K. <\/p>\n A. Executive Summary <\/p>\n B. Business Environment <\/p>\n C. Market Structure <\/p>\n D. Market Size, Growth and Major Suppliers <\/p>\n Major Product Development Opportunities <\/p>\n A. Instrumentation <\/p>\n B. Reagent Kits and Test Systems\/Panels <\/p>\n C. Computers, Software and Automation <\/p>\n D. Auxiliary Products <\/p>\n Design Criteria for Decentralized Testing Products <\/p>\n Alternative Market Penetration Strategies <\/p>\n A. Internal Development <\/p>\n B. Collaborative Arrangements <\/p>\n C. University Contracts <\/p>\n D. Distribution Strategies for Decentralized <\/p>\n Testing Markets <\/p>\n 1. Marketing Approaches <\/p>\n 2. Product Complexity <\/p>\n 3. Customer Preference <\/p>\n 4. Established Suppliers <\/p>\n 5. Emerging Suppliers <\/p>\n 6. Major Types of Distributors <\/p>\n 7. Market Segmentation <\/p>\n Potential Market Entry Barriers and Risks <\/p>\n A. Market Maturity <\/p>\n B. Cost Containment <\/p>\n C. Competition <\/p>\n D. Technological Edge and Limitations <\/p>\n E. Patent Protection <\/p>\n F. Regulatory Constraints <\/p>\n G. Decentralized Testing Market Challenges <\/p>\n Competitive Assessments- Abbott- Affymetrix- Beckman Coulter- Becton Dickinson- bioMerieux- Bio-Rad- Cepheid- Diamedix- DiaSorin- Eiken Chemical- Enzo Biochem- Fujirebio- Gen-Probe- Hologic- ID Biomedical- J&J Diagnostics- Kreatech- Life Technology- Lonza- Nanogen- Novartis Diagnostics- Qiagen- Roche- Scienion- Sequenom- SeraCare- Siemens- Takara Bio- Thermo Fisher- Wallac- Wako <\/p>\n List of Tables <\/p>\n Major Companies Developing or Marketing AIDS Tests <\/p>\n Major Companies Developing or Marketing Adenovirus <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Bartonella <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing <\/p>\n Campylobacter Tests <\/p>\n Major Companies Developing or Marketing Candida <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Chlamydia <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Clostridium <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Coronavirus <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Cryptosporidium <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing CMV Tests <\/p>\n Major Companies Developing or Marketing Echovirus <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Enterovirus <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing EBV Tests <\/p>\n Major Companies Developing or Marketing GiardiaTestsMajor Companies Developing or Marketing GonorrheaTestsMajor Companies Developing or Marketing HantavirusTestsMajor Companies Developing or Marketing HelicobacterPylori TestsMajor Companies Developing or Marketing HepatitisTestsMajor Companies Developing or Marketing HerpesTestsMajor Companies Developing or Marketing InfluenzaTestsMajor Companies Developing or Marketing LegionellaTestsMajor Companies Developing or Marketing Lyme DiseaseTestsMajor Companies Developing or Marketing LymphogranulomaTestsMajor Companies Developing or Marketing MalariaTestsMajor Companies Developing or Marketing MeaslesTestsMajor Companies Developing or Marketing MeningitisTests <\/p>\n Major Companies Developing or Marketing Microsporidium <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing <\/p>\n Mononucleosis Tests <\/p>\n Major Companies Developing or Marketing Mumps Tests <\/p>\n Major Companies Developing or Marketing Mycoplasma <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Papilloma <\/p>\n Virus Tests <\/p>\n Major Companies Developing or Marketing Parvovirus <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Pneumonia <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing RSV Tests <\/p>\n Major Companies Developing or Marketing Rotavirus <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Rubella <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Salmonella <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Septicemia <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Shigella <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Staphylococci <\/p>\n Tests <\/p>\n Major Companies Developing or MarketingStreptococci TestsMajor Companies Developing or Marketing SyphilisTestsMajor Companies Developing or Marketing ToxoplasmosisTestsMajor Companies Developing or Marketing TrichomonasTestsMajor Companies Developing or Marketing TuberculosisTestsMajor Companies Developing or Marketing West NileTestsMajor Companies Developing or Marketing Yersinia TestsWorldwide All Market Segments LaboratoriesPerforming Microbiology Tests by CountryWorldwide All Market Segments Total Microbiology TestVolume Forecast by CountryWorldwide All Market Segments Total MicrobiologyDiagnostics Market Forecast by CountryInfectious Disease Tests Major Issues and MarketPotential For Personal TestingU.K. Summary TableAll Infectious Diseases Test Volume and DiagnosticsSales Forecast by Market SegmentU.K.Laboratories Performing Infectious Disease Testsby Market Segment <\/p>\n U.K. <\/p>\n Hospital Laboratories Performing Infectious Disease <\/p>\n Tests by Bed Size <\/p>\n U.K. <\/p>\n Commercial\/Private Laboratories Performing Infectious <\/p>\n Disease Tests by Annual Test Volume <\/p>\n U.K. <\/p>\n All Market Segments Infectious Disease Test Volume Forecast <\/p>\n U.K. <\/p>\n Hospital Laboratories Infectious Disease Test Volume Forecast <\/p>\n U.K. <\/p>\n Blood Banks Infectious Disease Test Volume Forecast <\/p>\n U.K. <\/p>\n Public Health Laboratories Infectious Disease Test <\/p>\n Volume Forecast <\/p>\n U.K. <\/p>\n Commercial\/Private Laboratories Infectious Disease <\/p>\n Test Volume Forecast <\/p>\n U.K. <\/p>\n All Market Segments Infectious Disease Diagnostics <\/p>\n Market Forecast <\/p>\n U.K. <\/p>\n Hospital Laboratories Infectious Disease Diagnostics <\/p>\n Market Forecast <\/p>\n U.K. <\/p>\n Blood Banks Infectious Disease Diagnostics Market Forecast <\/p>\n U.K. <\/p>\n Public Health Laboratories Infectious Disease <\/p>\n Diagnostics Market Forecast <\/p>\n U.K.Commercial\/Private Laboratories Infectious DiseaseDiagnostics Market ForecastU.K.HIV or HIVI\/HIVII Test Volume and Diagnostics SalesForecast by Market SegmentU.K.HTLV I or HTLV I\/HTLV II Test Volume and DiagnosticsSales Forecast by Market SegmentU.K.HIVAg Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Western Blot\/Other Confirmatory Test Volume andDiagnostics Sales Forecast by Market SegmentU.K.AdenovirusTest Volume and Diagnostics Sales Forecast by Market SegmentU.K.AeromonadsTest Volume and Diagnostics Sales Forecast by Market SegmentU.K.BEATest Volume and Diagnostics Sales Forecast by Market Segment <\/p>\n U.K. <\/p>\n Blastocystis Hominis Test Volume and Diagnostics Sales <\/p>\n Forecast by Market Segment <\/p>\n U.K. <\/p>\n Campylobacter <\/p>\n Test Volume and Diagnostics Sales Forecast by Market Segment <\/p>\n U.K. <\/p>\n Candida <\/p>\n Test Volume and Diagnostics Sales Forecast by Market Segment <\/p>\n U.K. <\/p>\n Chancroid <\/p>\n Test Volume and Diagnostics Sales Forecast by Market Segment <\/p>\n U.K. <\/p>\n Chlamydia Test Volume and Diagnostics Sales Forecast by Market <\/p>\n Segment <\/p>\n U.K. <\/p>\n Clostridium Test Volume and Diagnostics Sales Forecast by <\/p>\n Market Segment <\/p>\n U.K. <\/p>\n Coronavirus Test Volume and Diagnostics Sales Forecast by <\/p>\n Market Segment <\/p>\n U.K. <\/p>\n CoxsackieVirus Test Volume and Diagnostics Sales Forecast by <\/p>\n Market Segment <\/p>\n U.K. <\/p>\n Cryptosporidium Test Volume and Diagnostics Sales Forecast by <\/p>\n Market Segment <\/p>\n U.K. <\/p>\n Cyclospora Test Volume and Diagnostics Sales Forecast by <\/p>\n Market Segment <\/p>\n U.K.CMV Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.E. Coli Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Echovirus Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Encephalitis Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.Enterovirus Test Volume and Diagnostics Sales Forecast byMarketSegmentU.K.EBV Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Giardia Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Gonorrhea Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Granuloma Inguinale Test Volume and Diagnostics SalesForecast by Market SegmentU.K.Helicobacter Pylori Test Volume and Diagnostics SalesForecast by Market Segment <\/p>\n U.K. <\/p>\n HAV NAT Test Volume and Diagnostics Sales Forecast by Market <\/p>\n Segment <\/p>\n U.K. <\/p>\n HBV NAT Test Volume and Diagnostics Sales Forecast by Market <\/p>\n Segment <\/p>\n U.K. <\/p>\n HbsAg Test Volume and Diagnostics Sales Forecast by Market <\/p>\n Segment <\/p>\n U.K. <\/p>\n Hepatitis C Test Volume and Diagnostics Sales Forecast by <\/p>\n Market Segment <\/p>\n U.K. <\/p>\n Anti-HBc Test Volume and Diagnostics Sales Forecast by Market <\/p>\n Segment <\/p>\n U.K. <\/p>\n Anti-HBs Test Volume and Diagnostics Sales Forecast by Market <\/p>\n Segment <\/p>\n U.K. <\/p>\n Anti-HAV Test Volume and Diagnostics Sales Forecast by Market <\/p>\n Segment <\/p>\n U.K. <\/p>\n Hepatitis Delta Test Volume and Diagnostics Sales <\/p>\n Forecast by Market Segment <\/p>\n U.K. <\/p>\n HBcAg Test Volume and Diagnostics Sales Forecast by Market <\/p>\n Segment <\/p>\n U.K.HBeAg Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Herpes Simplex I and II Test Volume and DiagnosticsSales Forecast by Market SegmentU.K.Herpes Type VI Test Volume and DiagnosticsSales Forecast by Market SegmentU.K.HTLV-I\/II Test Volume and DiagnosticsSales Forecast by Market SegmentU.K.Influenza Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Legionella Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.Lyme Disease Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.Lymphogranuloma Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.Malaria Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Measles Test Volume and Diagnostics Sales Forecast by MarketSegment <\/p>\n U.K. <\/p>\n Meningitis Test Volume and Diagnostics Sales Forecast by <\/p>\n Market Segment <\/p>\n U.K. <\/p>\n Microsporidium Test Volume and Diagnostics Sales Forecast by <\/p>\n Market Segment <\/p>\n U.K. <\/p>\n Mononucleosis Test Volume and Diagnostics Sales Forecast by <\/p>\n Market Segment <\/p>\n U.K. <\/p>\n Mumps Test Volume and Diagnostics Sales Forecast by Market <\/p>\n Segment <\/p>\n U.K. <\/p>\n Mycoplasma Test Volume and Diagnostics Sales Forecast by <\/p>\n Market Segment <\/p>\n U.K. <\/p>\n Papilloma Virus Test Volume and Diagnostics Sales Forecast by <\/p>\n Market Segment <\/p>\n U.K. <\/p>\n Parvovirus Test Volume and Diagnostics Sales Forecast by <\/p>\n Market Segment <\/p>\n U.K. <\/p>\n Pneumonia Test Volume and Diagnostics Sales Forecast by <\/p>\n Market Segment <\/p>\n U.K. <\/p>\n Polyomaviruses Test Volume and Diagnostics Sales <\/p>\n Forecast by Market Segment <\/p>\n U.K. <\/p>\n Pseudomonas Test Volume and Diagnostics Sales Forecast by <\/p>\n Market Segment <\/p>\n U.K.Rabies Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.RSV Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Rhinovirus Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.Rotavirus Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.Rubella Test Volume and Diagnostics Sales Forecast by MarketSegmentU.K.Salmonella Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.Septicemia Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.Shigella Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.Staphylococci Test Volume and Diagnostics Sales Forecast byMarket SegmentU.K.Streptococci Test Volume and Diagnostics Sales Forecast byMarket Segment <\/p>\n U.K. <\/p>\n Syphilis Test Volume and Diagnostics Sales Forecast by <\/p>\n Market Segment <\/p>\n U.K. <\/p>\n Toxoplasmosis Test Volume and Diagnostics Sales Forecast by <\/p>\n Market Segment <\/p>\n U.K. <\/p>\n Trichomonas Test Volume and Diagnostics Sales Forecast by <\/p>\n Market Segment <\/p>\n U.K. <\/p>\n Tuberculosis Test Volume and Diagnostics Sales Forecast by <\/p>\n Market Segment <\/p>\n U.K. <\/p>\n Vibrio Test Volume and Diagnostics Sales Forecast <\/p>\n by Market Segment <\/p>\n U.K. <\/p>\n West Nile Test Volume and Diagnostics Sales Forecast <\/p>\n by Market Segment <\/p>\n U.K. <\/p>\n Yersinia Test Volume and Diagnostics Sales Forecast <\/p>\n by Market Segment <\/p>\n U.K. <\/p>\n AIDS Testing Market Diagnostics Sales by Major <\/p>\n Supplier <\/p>\n U.K. <\/p>\n Campylobacter Testing Market Diagnostics Sales by <\/p>\n Major Supplier <\/p>\n U.K.Candida Testing Market Diagnostics Sales by MajorSupplierU.K.Gonorrhea Testing Market Diagnostics Sales byMajor SupplierU.K.Hepatitis Testing Market Diagnostics Sales by MajorSupplierU.K.Hepatitis C Testing Market Diagnostics Sales byMajor SupplierU.K.Influenza Testing Market Diagnostics Sales byMajor SupplierU.K.Mycoplasma Testing Market Diagnostics Sales byMajor SupplierU.K.Pneumonia Testing Market Diagnostics Sales by MajorSupplierU.K.RSV Testing Market Diagnostics Sales by Major SupplierU.K.Rubella Testing Market Diagnostics Sales by MajorSupplierU.K.Septicemia Testing Market Diagnostics Sales by MajorSupplier <\/p>\n U.K. <\/p>\n Shigella Testing Market Diagnostics Sales by Major <\/p>\n Supplier <\/p>\n U.K. <\/p>\n Streptococci Testing Market Diagnostics Sales by <\/p>\n Major Supplier <\/p>\n U.K. <\/p>\n Syphilis Testing Market Diagnostics Sales by Major <\/p>\n Supplier <\/p>\n U.K. <\/p>\n Tuberculosis Testing Market Diagnostics Sales by <\/p>\n Major Supplier <\/p>\n U.K. <\/p>\n Infectious Disease Diagnostic Testing Instrumentation <\/p>\n Major Systems Estimated Placements and Installed Base <\/p>\n To order this report:In Vitro Diagnostic Industry: Future UK Microbiology Testing Market Outlook <\/p>\n More <\/p>\n Market Research Report <\/p>\n Check our <\/p>\n Industry Analysis and Insights <\/p>\n Nicolas Bombourg Visit link: NEW YORK, Feb. 16, 2012 \/PRNewswire\/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Future UK Microbiology Testing Market Outlook http:\/\/www.reportlinker.com\/p0771119\/Future-UK-Microbiology-Testing-Market-Outlook.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic<\/a> Highlights Comprehensive 978-page analysis of the UK microbiology testing market Continue reading
Reportlinker
Email: nbo@reportlinker.com<\/a>
US: (805)652-2626
Intl: +1 805-652-2626 <\/p>\n<\/p>\n
\nFuture UK Microbiology Testing Market Outlook<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"